Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 33,035 matching trials from the live ClinicalTrials.gov search.
Conditions
Primary Sjögren Syndrome, Dry Eye
Interventions
0.005% Lacripep, 0.01% Lacripep, Placebo
Drug
Lead sponsor
TearSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Azusa, California + 31 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Differences in Effortful Control

NCT01852344
Conditions
Healthy
Interventions
Methylphenidate, Placebo, Easy Behavioral Task, Hard Behavioral Task
Drug · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

Pomalidomide for the Treatment of Bleeding in HHT

NCT03910244
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pomalidomide Oral Product, Placebo oral capsule
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 11 more
Conditions
Hypopituitarism
Interventions
Human Growth Hormone (1-134), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Alcohol Use Disorder
Interventions
Sunobinop, Placebo to match sunobinop
Drug
Lead sponsor
Knoa Pharma LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Dantrolene in Subarachnoid Hemorrhage

NCT01024972
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Dantrolene, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Healthy Participants
Interventions
AZD2389, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glendale, California
Conditions
Schizophrenia
Interventions
Basmisanil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 32 more
Conditions
Diabetes Mellitus, Type II
Interventions
Dutogliptin, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
98
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 84 more
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Escondido, California • Irvine, California + 10 more
Conditions
Major Depressive Disorder
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 46 more
Conditions
Insomnia, Depressive Disorder, Major
Interventions
Eszopiclone, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
21 Years to 64 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
65
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 62 more
Conditions
Hip Surgery Corrective, Anesthesia; Functional
Interventions
Drug group Fascia iliaca nerve block, Control group sham nerve block
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bones Stress Injury, Bone Stress Fracture
Interventions
Extracorporeal shockwave treatment (ESWT)., Sham Device
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Redwood City, California • Cambridge, Massachusetts + 1 more
Conditions
Hypertriglyceridemia, Type 2 Diabetes
Interventions
DS102, Placebo
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Huntington Park, California + 24 more
Conditions
Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
18 Years to 90 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pasedena, Texas
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Coronary Heart Disease
Interventions
DFV890, DFV890 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Northridge, California • Boca Raton, Florida • Jacksonville, Florida + 3 more
Conditions
Skin Diseases, Infectious
Interventions
Trimethoprim-sulfamethoxazole, Placebo group
Drug
Lead sponsor
St. Louis University
Other
Eligibility
3 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Healthy Volunteers
Interventions
PF-03882845 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Conditions
Healthy Volunteer
Interventions
ACHN-975, placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Dyskinesias, Parkinson Disease
Interventions
Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C, Part 1, Placebo Group, Part 2, JM-010 combination Group A, Part 2, JM-010 combination Group B, Part 2, JM-010 component Group C, Part 2, Placebo Group
Drug
Lead sponsor
Bukwang Pharmaceutical
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Miami, Florida • Detroit, Michigan
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone

NCT04313972
Conditions
Interstitial Cystitis, Painful Bladder Syndrome, Bladder Pain Syndrome, Low Dose Naltrexone, Low-dose Naltrexone, Naltrexone
Interventions
low-dose naltrexone, Placebo oral tablet
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Skokie, Illinois